Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3856-3865

  London, Cheryl A ^a,j   Malpas, Phyllis B ^b   Wood Follis, Stacey L ^b   Boucher, Joseph F ^b   Rusk, Anthony W ^c   Rosenberg, Mona P ^d   Henry, Carolyn J ^e   Mitchener, Kathy L ^f   Klein, Mary K ^g   Hintermeister, John G ^h,l   Bergman, Philip J ^i,m   Couto, Guillermo C ^j   Mauldin, Guy N ^k,n   Michels, Gina M ^b,o  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ZOETIS   (United States)

^c Friendship Hospital for Animals   (United States)

^d Veterinary Cancer Referral Group   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f Angel Care Cancer Clinic for Animals   (United States)

^g Southwest Radiation Oncology   (United States)

^h Veterinary Specialty Center   (United States)

ⁱ ANIMAL MEDICAL CENTER   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k LOUISIANA STATE UNIVERSITY   (United States)

^l Capital Area Veterinary Specialists   (United States)

^m BrightHeart Veterinary Centers   (United States)

ⁿ Western Veterinary Specialist Centre   (Canada)

^o PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PALLADIA; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SU 11654; TOCERANIB PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; DOG; DRUG SAFETY; FEMALE; MALE; MASTOCYTOMA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; TREATMENT RESPONSE; TUMOR GROWTH;

ANIMALS; ANOREXIA; DIARRHEA; DISEASE PROGRESSION; DOG DISEASES; DOGS; FEMALE; INDOLES; MALE; MAST-CELL SARCOMA; NEOPLASM RECURRENCE, LOCAL; PYRROLES; RANDOM ALLOCATION; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME; VOMITING;

EID: 66649106646     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1860     Document Type: Article

References (48)

1. London CA, Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract 2003;33:473-489 (Pubitemid 36798633)
2. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumors: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474
3. Scase TJ, Edwards D, Miller J, et al. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med 2006;20:151-158 (Pubitemid 43219385)
4. Davies DR, Wyatt KM, Jardine JE, Robertson ID, Irwin PJ. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. J Am Anim Hosp Assoc 2004;40:124-130 (Pubitemid 43180275)
5. McCaw DL, Miller MA, Ogilvie GK, et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Intern Med 1994;8:406-408
6. Rassnick KM , Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-605
7. Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2008;232:53-62.
8. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). J Vet Intern Med 1999;13:491-497
9. Thamm DH, TurekMM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 2006;68:581-587 (Pubitemid 44030769)
10. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand independent activation of c-kit product. J Clin Invest 1993;92:1736-1744 (Pubitemid 23304537)
11. Tsujimura T, Furitsu T, Morimoto M, et al. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P815 generated by a point mutation. Blood 1994;83:2619-2626 (Pubitemid 24135855)
12. Tsujimura T, Furitsu T, Morimoto M, et al. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 1995;106:377-385
13. Barbie DA, Deangelo DJ. Systemic mastocytosis: current classification and novel therapeutic options. Clin Adv Hematol Oncol 2006;4:768-775 (Pubitemid 44794707)
14. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30. (Pubitemid 46889785)
15. Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, VerstovsekS. Novel approaches in the treatment of systemic mastocytosis. Cancer 2006;107:1429-1439
16. London CA, Galli SJ, Yuuki T, Hu Z-Q, Helfand SC, Geissler EN. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-697 (Pubitemid 29181445)
17. Ma Y, Longley BJ, Wang X, Blount JL, Langley K, Caughey GH. Clustering of activating mutations in c-KIT's juxtamembrane coding region of canine mast cell neoplasms. J Invest Dermatol 1999;112:165-170 (Pubitemid 29061971)
18. Downing S, Chien MB, Kass PH, Moore PE, London CA. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002;63:1718-1723 (Pubitemid 35469646)
19. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 2006;8:104-111
20. Webster JD, Yuzbasiyan-Gurkan V, Miller RA, Kaneene JB, Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Vet Pathol 2007;44:298-308. (Pubitemid 46804656)
21. Letard S, Yang Y, Hanssens K, et al. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res 2008;6:1137-1145
22. Gari M, Goodeve A, Wilson G, et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999;105:894-900. (Pubitemid 29309094)
23. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1791-1799 (Pubitemid 43289355)
24. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t (8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904-3911 (Pubitemid 46630738)
25. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs wtih spontaneous malignancies. Clin Cancer Res 2003;9:2755-2768 (Pubitemid 36842122)
26. Pryer NK, Lee LB, Zadovaskaya R, et al. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003;9:5729-5734 (Pubitemid 37499497)
27. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007;7:127-134
28. Braconi C, Bracci R, Cellerino R. Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Curr Cancer Drug Targets 2008;8:359-366
29. Judson I, Demetri G. Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol 2007;18 Suppl 10:20-24
30. Couto GC. Principles of cancer treatment. In: Nelson RW, Couto CG, editors. Essentials of Small Animal Internal Medicine. 2nd ed. St. Louis (MO): Mosby; 1998. p. 1110.
31. CVM Guidelines and Guidance Documents: Good Clinical Practice. In: US Department of Health and Human Services FDA, Center of Veterinary Medicine, 2001.
32. Jones CL, Grahn RA, Chien MB, Lyons LA, London CA. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. J Vet Diagn Invest 2004;16:95-100. (Pubitemid 38377460)
33. Zavodovskaya R, Liao AT, Jones CL, et al. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs. Am J Vet Res 2006;67:633-641 (Pubitemid 44082173)
34. Grant IA, Rodriguez CO, Kent MS, Lord L, London CA. A Phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern Med 2008;22:388-393
35. Henry CJ, Downing S, Rosenthal RC, et al. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. Am J Vet Res 2007;68:1246-1251 (Pubitemid 350167926)
36. McCaw DL, Miller MA, Bergman PJ, et al. Vincristine therapy for mast cell tumors in dogs. J Vet Intern Med 1997;11:375-378
37. Rassnick KM, Bailey DM, Flory AB, et al. Efficacy of vinblastine for the treatment of canine mast cell tumors. J Vet Intern Med. In press 2008.
38. Camps-Palau MA, Leibman NF, Elmslie R, et al. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Vet Comp Onc 2007;5:156-167
39. Amagai Y, Tanaka A, Ohmori K, Matsuda H. Establishment of a novel high-affinity IgE receptor-positive canine mast cell line with wild-type c-kit receptors. Biochem Biophys Res Commun 2008;366:857-861
40. DeVinney R, Gold WM. Establishment of two dog mastocytoma cell lines in continuous culture. Am J Respir Cell Mol Biol 1990;3:413-420
41. Goetzl EJ, Phillips MJ, Gold WM. Stimulus specificity of the generation of leukotrienes by dog mastocytoma cells. J Exp Med 1983;158:731-737
42. Lin TY, Rush LJ, London CA. Generation and characterization of bone marrow-derived cultured canine mast cells. Vet Immunol Immunopathol 2006;113:37-52. (Pubitemid 44131569)
43. Takahashi T, Kitani S, Nagase M, et al. IgG-mediated histamine release from canine mastocytoma-derived cells. Int Arch Allergy Immunol 2001;125:228-235 (Pubitemid 32722294)
44. Rebuzzi L, Willmann M, SonneckK, et al. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol 2007;115:320-333 (Pubitemid 46109053)
45. Sleijfer S, Wiemer E, Seynaeve C, Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist 2007;12:719-726 (Pubitemid 47036206)
46. Fox LE, Rosenthal RC, Twedt DC, Dubielzig RR, MacEwen EG, Grauer GF. Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors. J Vet Intern Med 1990;4:242-246
47. Howard EB, Sawa TR, Nielsen SW, Kenyon AJ. Mastocytoma and gastroduodenal ulceration. Gastric and duodenal ulcers in dogs with mastocytoma. Pathol Vet 1969;6:146-158
48. Ishiguro T, Kadosawa T, Takagi S, et al. Relationship of disease progression and plasma histamine concentrations in 11 dogs with mast cell tumors. J Vet Intern Med 2003;17:194-198 (Pubitemid 37465354)